AIM ImmunoTech Reports Positive Clinical Progress in Pancreatic Cancer Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Clinical Trial Progress: AIM ImmunoTech has enrolled the final patient in the DURIPANC study, with a planned evaluation of the Clinical Benefit Rate (CBR) in December 2026, which could provide new treatment options for pancreatic cancer patients through the combination of Ampligen and AstraZeneca's Imfinzi.
- Survival Data: In a 57-subject Named Patient Program, Ampligen as a monotherapy demonstrated a median survival of 19.7 months, extending overall survival by 8.6 months compared to standard care, highlighting its potential to improve patient outcomes and quality of life.
- Immune Marker Analysis: Among patients with Neutrophil/Lymphocyte ratios below 4.5 in the NPP study, the overall median survival reached 34.8 months, an improvement of 22.3 months over historical controls, further validating the clinical value of Ampligen.
- Future Development Plans: AIM is planning a Phase 3 clinical trial for Ampligen in combination with a PD-1 inhibitor, aiming to demonstrate significant survival results, which could position AIM as a leader in pancreatic cancer research if successful.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AIM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AIM
Wall Street analysts forecast AIM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.516
Low
22.00
Averages
22.00
High
22.00
Current: 0.516
Low
22.00
Averages
22.00
High
22.00
No data
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AIM ImmunoTech Reports Positive Clinical Progress in Pancreatic Cancer Study
- Clinical Trial Progress: AIM ImmunoTech has enrolled the final patient in the DURIPANC study, with a planned evaluation of the Clinical Benefit Rate (CBR) in December 2026, which could provide new treatment options for pancreatic cancer patients through the combination of Ampligen and AstraZeneca's Imfinzi.
- Survival Data: In a 57-subject Named Patient Program, Ampligen as a monotherapy demonstrated a median survival of 19.7 months, extending overall survival by 8.6 months compared to standard care, highlighting its potential to improve patient outcomes and quality of life.
- Immune Marker Analysis: Among patients with Neutrophil/Lymphocyte ratios below 4.5 in the NPP study, the overall median survival reached 34.8 months, an improvement of 22.3 months over historical controls, further validating the clinical value of Ampligen.
- Future Development Plans: AIM is planning a Phase 3 clinical trial for Ampligen in combination with a PD-1 inhibitor, aiming to demonstrate significant survival results, which could position AIM as a leader in pancreatic cancer research if successful.
See More
Aimia Receives Approval for 5 Million Share Buyback
- Buyback Plan Approval: Aimia has received approval from the Toronto Stock Exchange to implement a normal course issuer bid, allowing for the repurchase of up to 5,012,419 common shares, representing 10% of the public float, aimed at enhancing shareholder value and reducing share price discount.
- Repurchase Details: As of May 29, 2026, Aimia has repurchased 3,725,400 shares at an average price of $2.87 per share, demonstrating the company's flexibility in capital allocation and its focus on market value.
- Market Operation Strategy: The company plans to conduct repurchases from June 8, 2025, to June 7, 2027, through TSX and other trading systems, with the ability to make block purchases weekly, ensuring flexible operations when market conditions permit.
- Future Outlook: Aimia believes that its current share price does not reflect its intrinsic value, and the buyback plan represents a prudent use of funds while supporting future strategic direction and capital allocation priorities, thereby enhancing market confidence.
See More
AIM ImmunoTech Hits Key Enrollment Milestone in Pancreatic Cancer Trial
- Enrollment Milestone Achieved: AIM ImmunoTech announced the completion of final patient enrollment in its pancreatic cancer trial ahead of schedule, resulting in a nearly 42% surge in stock price during Monday's opening trade, reflecting strong market confidence in its clinical progress.
- Clinical Trial Advancement: The company is continuing its Phase 3 trial planning while expanding its global regulatory and intellectual property footprint, which is expected to lay a solid foundation for the late-stage development of Ampligen and enhance its market competitiveness.
- Positive Clinical Data Support: The planned Phase 3 program is backed by data from a Dutch Named Patient Program and encouraging results from the ongoing DURIPANC study, indicating Ampligen's potential in pancreatic cancer treatment, with over 100 patients treated, accumulating valuable clinical experience.
- Future Development Outlook: AIM's CEO stated that the completion of Ampligen dosing is expected by December 2026, when the Clinical Benefit Rate (CBR) will be evaluated, marking a significant value-inflection point for the company and further attracting investor interest.
See More
Aimia Inc. Repurchases 224,400 Common Shares in May 2026
- Implementation of Buyback: Aimia Inc. repurchased and cancelled 224,400 common shares in May 2026 under its normal course issuer bid program, representing 0.25% of its total outstanding shares, demonstrating the company's commitment to enhancing shareholder value.
- Price Analysis: The shares were repurchased at a weighted-average price of $2.70 per share, totaling $606,220 excluding brokerage fees, reflecting the company's strategy to utilize funds effectively when market prices are below intrinsic value.
- Progress on Buyback: Since the announcement of its buyback initiative in June 2024, Aimia has repurchased and cancelled a total of 9,835,432 common shares, indicating that 62.9% of the allowable shares in the current buyback program have been completed, further boosting market confidence.
- Strategic Flexibility: Aimia believes that repurchasing common shares is an appropriate use of funds aimed at reducing the discount between market price and intrinsic value, while maintaining sufficient financial flexibility to support future strategic directions and capital allocation priorities.
See More
AIM ImmunoTech to Release Ebola Drug Research Video Presentation
- Video Release Announcement: AIM ImmunoTech has announced a video presentation titled 'Ebola: What This Means' scheduled for June 4, which will detail the potential role of its lead drug Ampligen in the prevention and early intervention of Ebola virus disease, aiming to raise public awareness about the outbreak.
- Clinical Research Progress: Ampligen (Rintatolimod) is currently undergoing a Phase 2 clinical study for locally advanced pancreatic cancer, and in preclinical mouse models, it demonstrated 100% protection against the Ebola virus at a 6mg/kg dose, indicating its potential efficacy in combating the virus.
- Regulatory Recognition: The U.S. FDA and European EMA have granted orphan drug designation for Ampligen in the context of Ebola virus disease, highlighting its potential in treating rare diseases and paving the way for future market opportunities.
- Stock Market Performance: AIM's stock has fluctuated between $0.21 and $19.73 over the past year, closing at $0.40 on Wednesday with a 72.37% increase, although it fell to $0.33 in overnight trading, reflecting a 19.28% decline.
See More
AIM ImmunoTech Announces Direct Offering of Shares
- Offering Size: AIM ImmunoTech has announced a registered direct offering of 7.51 million shares at a price of $0.325 per share, expected to generate approximately $2.4 million in gross proceeds, which will support the company's clinical drug supply and Phase 3 trial activities.
- Placement Details: The offering includes a concurrent private placement of unregistered Series I warrants to purchase up to 15.04 million shares at the same exercise price of $0.325, with warrants requiring stockholder approval and expiring five years from the initial exercise date.
- Market Performance: AIM ImmunoTech's stock has traded between $0.21 and $19.73 over the past year, closing at $0.25 on Wednesday, down 38.42%, indicating market caution regarding the company's financing plans.
- Strategic Use: The company intends to utilize the net proceeds from this offering for the manufacture of clinical drug supply, planned Phase 3 clinical trial activities, and working capital, aiming to advance the development of its lead investigational product, Ampligen.
See More
AIM ImmunoTech Reports Positive Clinical Progress in Pancreatic Cancer Study
- Clinical Trial Progress: AIM ImmunoTech has enrolled the final patient in the DURIPANC study, with a planned evaluation of the Clinical Benefit Rate (CBR) in December 2026, which could provide new treatment options for pancreatic cancer patients through the combination of Ampligen and AstraZeneca's Imfinzi.
- Survival Data: In a 57-subject Named Patient Program, Ampligen as a monotherapy demonstrated a median survival of 19.7 months, extending overall survival by 8.6 months compared to standard care, highlighting its potential to improve patient outcomes and quality of life.
- Immune Marker Analysis: Among patients with Neutrophil/Lymphocyte ratios below 4.5 in the NPP study, the overall median survival reached 34.8 months, an improvement of 22.3 months over historical controls, further validating the clinical value of Ampligen.
- Future Development Plans: AIM is planning a Phase 3 clinical trial for Ampligen in combination with a PD-1 inhibitor, aiming to demonstrate significant survival results, which could position AIM as a leader in pancreatic cancer research if successful.
See More
Aimia Receives Approval for 5 Million Share Buyback
- Buyback Plan Approval: Aimia has received approval from the Toronto Stock Exchange to implement a normal course issuer bid, allowing for the repurchase of up to 5,012,419 common shares, representing 10% of the public float, aimed at enhancing shareholder value and reducing share price discount.
- Repurchase Details: As of May 29, 2026, Aimia has repurchased 3,725,400 shares at an average price of $2.87 per share, demonstrating the company's flexibility in capital allocation and its focus on market value.
- Market Operation Strategy: The company plans to conduct repurchases from June 8, 2025, to June 7, 2027, through TSX and other trading systems, with the ability to make block purchases weekly, ensuring flexible operations when market conditions permit.
- Future Outlook: Aimia believes that its current share price does not reflect its intrinsic value, and the buyback plan represents a prudent use of funds while supporting future strategic direction and capital allocation priorities, thereby enhancing market confidence.
See More
AIM ImmunoTech Hits Key Enrollment Milestone in Pancreatic Cancer Trial
- Enrollment Milestone Achieved: AIM ImmunoTech announced the completion of final patient enrollment in its pancreatic cancer trial ahead of schedule, resulting in a nearly 42% surge in stock price during Monday's opening trade, reflecting strong market confidence in its clinical progress.
- Clinical Trial Advancement: The company is continuing its Phase 3 trial planning while expanding its global regulatory and intellectual property footprint, which is expected to lay a solid foundation for the late-stage development of Ampligen and enhance its market competitiveness.
- Positive Clinical Data Support: The planned Phase 3 program is backed by data from a Dutch Named Patient Program and encouraging results from the ongoing DURIPANC study, indicating Ampligen's potential in pancreatic cancer treatment, with over 100 patients treated, accumulating valuable clinical experience.
- Future Development Outlook: AIM's CEO stated that the completion of Ampligen dosing is expected by December 2026, when the Clinical Benefit Rate (CBR) will be evaluated, marking a significant value-inflection point for the company and further attracting investor interest.
See More
Aimia Inc. Repurchases 224,400 Common Shares in May 2026
- Implementation of Buyback: Aimia Inc. repurchased and cancelled 224,400 common shares in May 2026 under its normal course issuer bid program, representing 0.25% of its total outstanding shares, demonstrating the company's commitment to enhancing shareholder value.
- Price Analysis: The shares were repurchased at a weighted-average price of $2.70 per share, totaling $606,220 excluding brokerage fees, reflecting the company's strategy to utilize funds effectively when market prices are below intrinsic value.
- Progress on Buyback: Since the announcement of its buyback initiative in June 2024, Aimia has repurchased and cancelled a total of 9,835,432 common shares, indicating that 62.9% of the allowable shares in the current buyback program have been completed, further boosting market confidence.
- Strategic Flexibility: Aimia believes that repurchasing common shares is an appropriate use of funds aimed at reducing the discount between market price and intrinsic value, while maintaining sufficient financial flexibility to support future strategic directions and capital allocation priorities.
See More
AIM ImmunoTech to Release Ebola Drug Research Video Presentation
- Video Release Announcement: AIM ImmunoTech has announced a video presentation titled 'Ebola: What This Means' scheduled for June 4, which will detail the potential role of its lead drug Ampligen in the prevention and early intervention of Ebola virus disease, aiming to raise public awareness about the outbreak.
- Clinical Research Progress: Ampligen (Rintatolimod) is currently undergoing a Phase 2 clinical study for locally advanced pancreatic cancer, and in preclinical mouse models, it demonstrated 100% protection against the Ebola virus at a 6mg/kg dose, indicating its potential efficacy in combating the virus.
- Regulatory Recognition: The U.S. FDA and European EMA have granted orphan drug designation for Ampligen in the context of Ebola virus disease, highlighting its potential in treating rare diseases and paving the way for future market opportunities.
- Stock Market Performance: AIM's stock has fluctuated between $0.21 and $19.73 over the past year, closing at $0.40 on Wednesday with a 72.37% increase, although it fell to $0.33 in overnight trading, reflecting a 19.28% decline.
See More
AIM ImmunoTech Announces Direct Offering of Shares
- Offering Size: AIM ImmunoTech has announced a registered direct offering of 7.51 million shares at a price of $0.325 per share, expected to generate approximately $2.4 million in gross proceeds, which will support the company's clinical drug supply and Phase 3 trial activities.
- Placement Details: The offering includes a concurrent private placement of unregistered Series I warrants to purchase up to 15.04 million shares at the same exercise price of $0.325, with warrants requiring stockholder approval and expiring five years from the initial exercise date.
- Market Performance: AIM ImmunoTech's stock has traded between $0.21 and $19.73 over the past year, closing at $0.25 on Wednesday, down 38.42%, indicating market caution regarding the company's financing plans.
- Strategic Use: The company intends to utilize the net proceeds from this offering for the manufacture of clinical drug supply, planned Phase 3 clinical trial activities, and working capital, aiming to advance the development of its lead investigational product, Ampligen.
See More
